Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (211-220 of 315) with videos related to

Pageof 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignanciesUdai Banerji, Anne O'Donnell, Michelle Scurr, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Bioorganic & Medicinal Chemistry|July 3, 2007
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitorsMasahiko Hayakawa, Ken-Ichi Kawaguchi, Hiroyuki Kaizawa, et al.
Molecular Cancer Therapeutics|September 3, 2011
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivoAmir Faisal, Lynsey Vaughan, Vassilios Bavetsias, et al.
Oncogene|February 26, 2020
Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinasesChi Zhang, Simon R Stockwell, May Elbanna, et al.
Oncogene|July 13, 2019
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinasesChi Zhang, Simon R Stockwell, May Elbanna, et al.
Journal of Molecular Biology|February 6, 2007
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimeraThomas G Davies, Marcel L Verdonk, Brent Graham, et al.
Plos One|July 14, 2017
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cellsNada M S Al-Saffar, Alice Agliano, Lynley V Marshall, et al.
Nature Communications|February 17, 2026
R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancersChi Zhang, Yu-Jing Lu, Bingjie Chen, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2006
4-Amino derivatives of the Hsp90 inhibitor CCT018159Xavier Barril, Mandy C Beswick, Adam Collier, et al.
Pageof 32

Showing results (211-220 of 315) with videos related to

Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignanciesUdai Banerji, Anne O'Donnell, Michelle Scurr, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Bioorganic & Medicinal Chemistry|July 3, 2007
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitorsMasahiko Hayakawa, Ken-Ichi Kawaguchi, Hiroyuki Kaizawa, et al.
Molecular Cancer Therapeutics|September 3, 2011
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivoAmir Faisal, Lynsey Vaughan, Vassilios Bavetsias, et al.
Oncogene|February 26, 2020
Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinasesChi Zhang, Simon R Stockwell, May Elbanna, et al.
Oncogene|July 13, 2019
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinasesChi Zhang, Simon R Stockwell, May Elbanna, et al.
Journal of Molecular Biology|February 6, 2007
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimeraThomas G Davies, Marcel L Verdonk, Brent Graham, et al.
Plos One|July 14, 2017
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cellsNada M S Al-Saffar, Alice Agliano, Lynley V Marshall, et al.
Nature Communications|February 17, 2026
R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancersChi Zhang, Yu-Jing Lu, Bingjie Chen, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2006
4-Amino derivatives of the Hsp90 inhibitor CCT018159Xavier Barril, Mandy C Beswick, Adam Collier, et al.
Pageof 32